Supplementary Table 4.

Univariate and multivariate analyses of DFS and OS in ALK negative patients.

Variable	DFS					OS
	Univariate analysis			Multivariate analysis		Univariate analysis			Multivariate analysis
	n	Median DFS (mo)	P*	HR (95%CI)	P*	n	Median OS (mo)	P*	HR (95%CI)	P*
Age (years)
≤60	295	25.85	0.646			295	31.59	0.694
>60	225	25.96				225	30.51
Sex
Male	242	25.69	0.675			242	30.75	0.269
Female	278	26.09				278	31.45
Smoking history
Former/current smoker	258	25.41	0.757			258	30.66	0.451
Never smoker	254	26.21				254	31.30
Pathological stage
I	261	28.19	0.026	1.450 (1.265, 1.662)	≤0.001	261	31.75	0.005		0.370
II	81	25.69				81	30.99
IIIA	165	22.78				165	30.34
IIIB	13	20.86				13	29.29
Tumor size
≤3 cm	312	26.39	0.006		0.583	312	30.64	0.375
>3 cm	208	25.17				208	31.84
Regional LN metastasis
No	312	27.81	≤0.001		0.292	312	31.46	≤0.001	2.674 (1.862, 3.842)	≤0.001
Yes	208	23.04				208	30.61
Surgical resection
Pneumonectomy	34	23.30	0.029	1.376 (1.070, 1.770)	0.013	34	30.57	0.030	1.482 (1.087, 2.019)	0.013
Lobectomy	466	25.99				466	30.96
Wedge resection	16	28.39				16	35.49
Adjuvant treatment
No	283	25.13	0.761			283	29.21	0.045	0.440 (0.304, 0.637)	≤0.001
Yes	237	26.82				237	33.41
CEA
≤5.0 ng/ml	314	27.37	≤0.001	1.367 (1.046, 1.787)	0.022	314	31.46	0.034		0.479
>5.0 ng/ml	204	23.65				204	30.63
SCCA
≤1.5 ng/ml	480	26.15	0.153			480	31.47	0.126
>1.5 ng/ml	38	22.82				38	26.85
Cyfra21–1
≤3.3 ng/ml	346	26.87	0.001	1.421 (1.095, 1.843)	0.008	346	31.85	≤0.001	1.839 (1.313, 2.575)	≤0.001
>3.3 ng/ml	172	23.98				172	29.68
NSE
≤15.2 ng/ml	407	25.96	0.205			407	31.05	0.189
>15.2 ng/ml	110	25.65				110	31.44

LN – lymph node; CEA – carcinoembryonic antigen;Cyfra21-1 – cytokeratin-19 fragments; SCCA – squamous cell carcinoma antigen; NSE – neuron-specific enolase; DFS – disease-free survival; OS – overall survival; HR – hazard ratio; CI – confidence interval.